Direct Detection of Feline Coronavirus by Three Rapid Antigen Immunochromatographic Tests and by Real-Time PCR in Cat Shelters

0 Comments

The aim of this study was the direct detection of feline coronavirus by real-time PCR and by three different rapid immunochromatographic (RIM) tests detecting antigens in faecal samples of shelter cats. Based on sensitivity and specificity calculated for each of the RIM tests, the utility of RIM tests was compared. Seventy faecal samples originating from shelter cats housed in quarantine were examined. Out of 70 samples analyzed by real-time PCR, 44 (62.9%) were positive. Significantly more cats (p < 0.05) tested positive than negative. Neither age nor sex of the cats played a significant role (p > 0.05) in the shedding status of the virus.

The sensitivity of the RIM tests was found to be at low (<35%; RIM tests A and C) to satisfactory level (>50%, RIM test B). The number of virus particles determined by real-time RT-PCR analysis did not significantly correlate with the results detected by any of the RIM tests (p > 0.05). The results of this study indicate  INDICAID Antigen Test  that the use of rapid antigen RIM tests in routine screening of FCoV shedding status in shelter cats is limited due to the occurrence of a high number of false negative results.

Isolation is recommended during acute infection with SARS-CoV-2, the virus that causes COVID-19, but the duration of infectiousness varies among individual persons.

  • Rapid antigen test results have been correlated with detection of viable virus (1-3) and might inform isolation guidance, but data are limited for the recently emerged SARS-CoV-2 B.1.1.529 (Omicron) variant.
  • On January 5, 2022, the Yukon-Kuskokwim Health Corporation (YKHC) recommended that persons with SARS-CoV-2 infection isolate for 10 days after symptom onset (or, for asymptomatic persons, 10 days after a positive nucleic acid amplification or antigen test result). However, isolation could end after 5-9 days if symptoms were resolving or absent, fever was absent for ≥24 hours without fever-reducing medications, and an Abbott BinaxNOW COVID-19 Ag (BinaxNOW) rapid antigen test result was negative.
  • Antigen test results and associated individual characteristics were analyzed among 3,502 infections reported to YKHC during January 1-February 9, 2022. After 5-9 days, 396 of 729 persons evaluated (54.3%) had a positive antigen test result, with a declining percentage positive over time.
  • In a multivariable model, a positive antigen test result was more likely after 5 days compared with 9 days (adjusted odds ratio [aOR] = 6.39) or after symptomatic infection (aOR = 9.63), and less likely after previous infection (aOR = 0.30), receipt of a primary COVID-19 vaccination series (aOR = 0.60), or after both previous infection and receipt of a primary COVID-19 vaccination series (aOR = 0.17).
  • Antigen tests might be a useful tool to guide recommendations for isolation after SARS-CoV-2 infection. During the 10 days after infection, persons might be infectious to others and are recommended to wear a well-fitting mask when around others, even if ending isolation after 5 days.

Since autumn 2020, rapid antigen tests (RATs) have been implemented in several countries as an important pillar of the national testing strategy to rapidly screen for infections on site during the SARS-CoV-2 pandemic.

The current surge in infection rates around the globe is driven by the variant of concern (VoC) omicron (B.1.1.529). Here, we evaluated the performance of nine SARS-CoV-2 RATs in a single-centre laboratory study. We examined a total of 115 SARS-CoV-2 PCR-negative and 166 SARS-CoV-2 PCR-positive respiratory swab samples (101 omicron, 65 delta (B.1.617.2)) collected from October 2021 until January 2022 as well as cell culture-expanded clinical isolates of both VoCs. In an assessment of the analytical sensitivity in clinical specimen, the 50% limit of detection (LoD50) ranged from 1.77 × 106 to 7.03 × 107 RNA copies subjected to the RAT for omicron compared to 1.32 × 105 to 2.05 × 106 for delta.

To score positive in these point-of-care tests, up to 10-fold (LoD50) or 101-fold (LoD95) higher virus loads were required for omicron- compared to delta-containing samples. The rates of true positive test results for omicron samples in the highest virus load category (Ct values < 25) ranged between 31.4 and 77.8%, while they dropped to 0-8.3% for samples with intermediate Ct values (25-30). Of note, testing of expanded virus stocks suggested a comparable RAT sensitivity of both VoCs, questioning the predictive value of this type of in vitro-studies for clinical performance. Given their importance for national test strategies in the current omicron wave, awareness must be increased for the reduced detection rate of omicron infections by RATs and a short list of suitable RATs that fulfill the minimal requirements of performance should be rapidly disclosed.

China’s NMPA perspective on the clinical performance of SARS-CoV-2 antigen test reagents

 

  1. The COVID-19 pandemic continues to spread all over the world. In the process of emergency use authorization, the Center for Medical Device Evaluation of the China National Medical Products Administration issued ‘Key Points of Technical Review for the Registration of SARS-CoV-2 Antigen/Antibody Detection Reagents’ as the guidance of registration of antigen and antibody test reagents for the industry.
  2. In this document, clinical evaluation requirements of antigen detection reagents are elaborated. Based on the Key Points document and the authors’ review practice, this article explains the evaluation methods and requirements of clinical performance of SARS-CoV-2 antigen-detecting rapid diagnostic tests, then analyzes the application scenarios and intended use of antigen detection reagents.
  3. The antigen-based rapid diagnostic test (Ag-RDT) using saliva specimens is fast, noninvasive, and suitable for SARS-CoV-2 self-testing, unlike nasopharyngeal swab (NPS) testing.
  4. We evaluated a novel Beanguard gargle (BG)-based virus collection method that can be applied to Ag-RDT as an alternative to the current RT-PCR with an NPS for early diagnosis of COVID-19.
  5. This clinical trial comprised 102 COVID-19-positive patients hospitalized after a governmental screening process and 100 healthy individuals.
  6. Paired NPS and BG-based saliva specimens from COVID-19 patients and healthy individuals were analyzed using NPS-RT-PCR, BG-RT-PCR, and BG-Ag-RDTs, whose diagnostic performance for detecting SARS-CoV-2 was compared.

BG-Ag-RDTs showed high sensitivity (97.8%) and specificity (100%) in 45 patients within 6 days of illness and detected all cases of SARS-CoV-2 Alpha and Delta variants. In 11 asymptomatic active COVID-19 cases, both BG-Ag-RDTs and BG-RT-PCR showed sensitivities and specificities of 100%. Sensitivities of BG-Ag-RDT and BG-RT-PCR toward salivary viral detection were highly concordant, with no discrimination between symptomatic (97.0%), asymptomatic (100%), or SARS-CoV-2 variant (100%) cases.

TruStrip RDT Human Procalcitonin (PCT) Rapid Test cards, 25 tests/pack

PCT-RDT-25 Alpha Diagnostics 1 pack 351.6 EUR

TruStrip RDT Human Serum Amyloid A (SAA) Rapid Test cards, 25 tests/pack

SAA-RDT-25 Alpha Diagnostics 1 pack 351.6 EUR

Human Rena-strip Kit, 25 tests

H-RENA-LF-025 BioAssayWorks 25 tests 617.3 EUR

Rat Rena-strip Kit, 25 tests

R-RENA-LF-025 BioAssayWorks 25 tests 617.3 EUR

TruStrip RDT 5-minute Horse meat detection/adulteration rapid test cards, 25 tests/pk

RDT-6050H-25 Alpha Diagnostics 1 pk 351.6 EUR

MTBK_20640-25

AR02-P0011-25 Abfrontier 25ug 567.6 EUR

Rv0351 (GrpE)-25

AR02-P0003-25 Abfrontier 25ug 151.2 EUR

Rv1009 (RpfB)-25

AR02-P0006-25 Abfrontier 25ug 567.6 EUR

Rv2450c (RpfE)-25

AR02-P0007-25 Abfrontier 25ug 567.6 EUR

Rv3875 (esxA)-25

AR02-P0008-25 Abfrontier 25ug 567.6 EUR

Rv2031c(HspX)-25

AR02-P0009-25 Abfrontier 25ug 567.6 EUR

Rv3131 (NfnB)-25

AR02-P0010-25 Abfrontier 25ug 567.6 EUR

Cardboard freezer box, hinged lid, insert for 25 snap-cap 5ml tubes, 5.25 x 5.25 x 3 inches

C2580-25 MTC Bio 5/pack 76.04 EUR

26795 25 CLOSURE NTRL 25MM

26795-25 CORNING 50/pk 115.2 EUR

AXYGEN® 25-WELL COMB FOR USE WITH 10 CM GEL BOX, 1.0 MM THICKNESS

HGB10-25-1 CORNING 1/pk 70.8 EUR

AXYGEN® 25-WELL COMB FOR USE WITH 10 CM GEL BOX, 2.0 MM THICKNESS

HGB10-25-2 CORNING 1/pk 70.8 EUR

AXYGEN® 25-WELL COMB FOR USE WITH 20 CM GEL BOX, 1.0 MM THICKNESS

HGB20-25-1 CORNING 1/pk 82.8 EUR

TruStrip RDT Anthrax Protective antigen 83 (PA83) Rapid Test cards, 25/pk

800-100-RDT-25 Alpha Diagnostics 1 pk 489.6 EUR

Mouse IL-25 ELISA Kit, 96 tests, Quantitative

MIL-025-170 Alpha Diagnostics 1 kit 607.2 EUR

Nori® Human Myoglobin POCT Systems-25 Tests

GR220006 Genorise Scientific 25 Tests 358.8 EUR

Nori® Human Myeloperoxidase POCT Systems-25 Tests

GR220007 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human CRP POCT Systems-25 Tests

GR220008 Genorise Scientific 25 Tests 358.8 EUR

Nori® Human GPBB POCT Systems-25 Tests

GR220009 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human ANP POCT Systems-25 Tests

GR220010 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human MyBPC3 POCT Systems-25 Tests

GR220012 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human PAPPA POCT Systems-25 Tests

GR220014 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human Copeptin POCT Systems-25 Tests

GR220015 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human ST2 POCT Systems-25 Tests

GR220016 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human MMP2 POCT Systems-25 Tests

GR220017 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human sPLA2 POCT Systems-25 Tests

GR220018 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine Myoglobin POCT Systems-25 Tests

GR221006 Genorise Scientific 25 Tests 358.8 EUR

Nori® Canine Myeloperoxidase POCT Systems-25 Tests

GR221007 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine CRP POCT Systems-25 Tests

GR221008 Genorise Scientific 25 Tests 358.8 EUR

Nori® Canine GPBB POCT Systems-25 Tests

GR221009 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine ANP POCT Systems-25 Tests

GR221010 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine MyBPC3 POCT Systems-25 Tests

GR221012 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine PAPPA POCT Systems-25 Tests

GR221014 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine Copeptin POCT Systems-25 Tests

GR221015 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine ST2 POCT Systems-25 Tests

GR221016 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine MMP2 POCT Systems-25 Tests

GR221017 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine sPLA2 POCT Systems-25 Tests

GR221018 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline Myoglobin POCT Systems-25 Tests

GR222006 Genorise Scientific 25 Tests 358.8 EUR

Nori® Feline Myeloperoxidase POCT Systems-25 Tests

GR222007 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline CRP POCT Systems-25 Tests

GR222008 Genorise Scientific 25 Tests 358.8 EUR

Nori® Feline GPBB POCT Systems-25 Tests

GR222009 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline ANP POCT Systems-25 Tests

GR222010 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline MyBPC3 POCT Systems-25 Tests

GR222012 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline PAPPA POCT Systems-25 Tests

GR222014 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline Copeptin POCT Systems-25 Tests

GR222015 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline ST2 POCT Systems-25 Tests

GR222016 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline MMP2 POCT Systems-25 Tests

GR222017 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline sPLA2 POCT Systems-25 Tests

GR222018 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine Myoglobin POCT Systems-25 Tests

GR223006 Genorise Scientific 25 Tests 358.8 EUR

Nori® Equine Myeloperoxidase POCT Systems-25 Tests

GR223007 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine CRP POCT Systems-25 Tests

GR223008 Genorise Scientific 25 Tests 358.8 EUR

Nori® Equine GPBB POCT Systems-25 Tests

GR223009 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine ANP POCT Systems-25 Tests

GR223010 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine MyBPC3 POCT Systems-25 Tests

GR223012 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine PAPPA POCT Systems-25 Tests

GR223014 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine Copeptin POCT Systems-25 Tests

GR223015 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine ST2 POCT Systems-25 Tests

GR223016 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine MMP2 POCT Systems-25 Tests

GR223017 Genorise Scientific 25 Tests 741.6 EUR

Nori® Equine sPLA2 POCT Systems-25 Tests

GR223018 Genorise Scientific 25 Tests 741.6 EUR

Amyloid Beta-peptide (25-35) (human)

A1039-25 ApexBio 25 mg 606 EUR

Express Plasmid Midiprep Kit (25 min)

K1323-25 Biovision 561.6 EUR

Express Plasmid Maxiprep Kit (25 min)

K1324-25 Biovision 732 EUR

2.5x14 cellogel 250µ (25)

EHCA1200-ST06-25 Consort ea 45.6 EUR

2.5x14 cellogel 200µ (25)

EHCA1200-ST07-25 Consort ea 45.6 EUR

2.5x17 cellogel 250µ (25)

EHCA1200-ST11-25 Consort ea 49.2 EUR

2.5x17 cellogel 200µ (25)

EHCA1200-ST12-25 Consort ea 49.2 EUR

5.7x13 cellogel 250µ (25)

EHCA1200-ST29U-25 Consort ea 72 EUR

5.7x14 cellogel 250µ (25)

EHCA1200-ST31-25 Consort ea 63.6 EUR

5.7x14 cellogel 200µ (25)

EHCA1200-ST32-25 Consort ea 63.6 EUR

5.7x14 cellogel 500µ (25)

EHCA1200-ST34-25 Consort ea 72 EUR

Rv2769c (PE27 protein)-25

AR02-P0001-25 Abfrontier 25ug 243.6 EUR

25-place microscope slide box (for 75 x 25 mm slides)

PO202 FD Neurotechnologies each 73.2 EUR

F-Box Only Protein 25 (FBXO25) Antibody

20-abx318182 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Agouti-related Protein (AGRP) (25-82), human

A1134-25 ApexBio 25 mg 1813.2 EUR

DiaEasy? Dialyzer (3 ml) MWCO 25 kDa

K1015-25 Biovision 588 EUR

DiaEasy? Dialyzer (250 µl) MWCO 25 kDa

K1022-25 Biovision 418.8 EUR

DiagNano Fluorophore Labeled Gold Nanoparticles, 25 nm

GFL-25 Creative Diagnostics 1 mL 1263.6 EUR

Nori® Human H-FABP POCT Systems-25 Tests

GR220004 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human NT-proBNP POCT Systems-25 Tests

GR220005 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human Lp-PLA2 POCT Systems-25 Tests

GR220011 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human GDF-15 POCT Systems-25 Tests

GR220013 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human Endothelin-1 POCT Systems-25 Tests

GR220019 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human Galectin-3 POCT Systems-25 Tests

GR220020 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human IL-6 POCT Systems-25 Tests

GR220022 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human TNF-alpha POCT Systems-25 Tests

GR220023 Genorise Scientific 25 Tests 741.6 EUR

Nori® Human Interferon Gamma POCT Systems-25 Tests

GR220024 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine H-FABP POCT Systems-25 Tests

GR221004 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine NT-proBNP POCT Systems-25 Tests

GR221005 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine Lp-PLA2 POCT Systems-25 Tests

GR221011 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine GDF-15 POCT Systems-25 Tests

GR221013 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine Endothelin-1 POCT Systems-25 Tests

GR221019 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine Galectin-3 POCT Systems-25 Tests

GR221020 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine IL-6 POCT Systems-25 Tests

GR221022 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine TNF-alpha POCT Systems-25 Tests

GR221023 Genorise Scientific 25 Tests 741.6 EUR

Nori® Canine Interferon Gamma POCT Systems-25 Tests

GR221024 Genorise Scientific 25 Tests 741.6 EUR

Nori® Feline H-FABP POCT Systems-25 Tests

GR222004 Genorise Scientific 25 Tests 741.6 EUR

The intermolecular interactions between SARS-CoV-2 spike proteins and truncated canavalin, an active ingredient from the bean extract (BE), were observed in terms of physicochemical properties. The detachment of the SARS-CoV-2 receptor-binding domain from hACE2 increased as the BE concentration increased, allowing the release of the virus from hACE2 for early diagnosis.Using BG-based saliva specimens remarkably enhances the Ag-RDT diagnostic performance as an alternative to NPS and enables noninvasive, rapid, and accurate COVID-19 self-testing and mass screening, supporting efficient COVID-19 management

Leave a Reply

Your email address will not be published. Required fields are marked *